We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+8.61%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$5.42B
AUM Growth
-$3.38B
Cap. Flow
-$3.75B
Cap. Flow %
-69.25%
Top 10 Hldgs %
40.63%
Holding
1,042
New
84
Increased
109
Reduced
414
Closed
284
Avg Time Held Equity + Options
3.7 quarters
Top 10 Avg Time Held Equity + Options
0.5 quarters
Top 20 Avg Time Held Equity + Options
0.8 quarters
Avg Time Held Equity only
3.7 quarters
Top 10 Avg Time Held Equity only
0.5 quarters
Top 20 Avg Time Held Equity only
0.8 quarters

Sector Composition

Rank Sector Weight
1 Financials 25.7%
2 Technology 18.31%
3 Healthcare 15.11%
4 Miscellaneous 11.75%
5 Real Estate 10.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
DBTX
601
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$385K 0.01%
187,966
+30,221
+19% +$92.1K
2022 Q2
2 quarters
PCVX icon
602
Vaxcyte
PCVX
$10.5B
$369K 0.01%
+7,687
New +$302K
2022 Q4
0 quarters
SPR icon
603
PUT
DELISTED
Spirit AeroSystems
SPR
$366K 0.01%
32,200
– –
2021 Q2
6 quarters
TREE icon
604
PUT
LendingTree
TREE
$348M
$340K 0.01%
40,000
– –
2022 Q3
1 quarter
PRAX icon
605
Praxis Precision Medicines
PRAX
$6.79B
$327K 0.01%
9,166
+1,448
+19% +$45.2K
2022 Q1
3 quarters
STWD icon
606
PUT
Starwood Property Trust
STWD
$4.62B
$317K 0.01%
71,100
-380,000
-84% -$7.57M
2021 Q2
6 quarters
F icon
607
PUT
Ford
F
$48.2B
$316K 0.01%
423,500
– –
2022 Q2
2 quarters
CTMX icon
608
CytomX Therapeutics
CTMX
$508M
$313K 0.01%
+195,388
New +$289K
2022 Q4
0 quarters
RVLP
609
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$310K 0.01%
276,428
– –
2022 Q3
1 quarter
EVLVW icon
610
DELISTED
Evolv Technologies Warrant
EVLVW
$307K 0.01%
708,885
-6,900
-1% -$3.45K
2021 Q3
5 quarters
XRX icon
611
PUT
Xerox
XRX
$373M
$290K 0.01%
42,700
– –
2021 Q2
6 quarters
ABOS icon
612
Acumen Pharmaceuticals
ABOS
$131M
$289K 0.01%
+53,436
New +$359K
2022 Q4
0 quarters
AKTS icon
613
DELISTED
Akoustis Technologies Inc
AKTS
$282K 0.01%
+100,000
New +$314K
2022 Q4
0 quarters
VNET icon
614
VNET Group
VNET
$1.5B
$264K ﹤0.01%
46,598
-1,449,721
-97% -$7.47M
2022 Q2
2 quarters
DAL icon
615
PUT
Delta Air Lines
DAL
$52.4B
$249K ﹤0.01%
28,200
– –
2021 Q2
6 quarters
LVTX icon
616
DELISTED
LAVA Therapeutics
LVTX
$249K ﹤0.01%
71,272
-3,728
-5% -$17.1K
2022 Q3
1 quarter
VSTM icon
617
Verastem
VSTM
$675M
$228K ﹤0.01%
47,227
-26,868
-36% -$132K
2022 Q1
3 quarters
WYNN icon
618
PUT
Wynn Resorts
WYNN
$7.79B
$207K ﹤0.01%
7,000
– –
2021 Q3
5 quarters
SAVE icon
619
PUT
DELISTED
Spirit Airlines, Inc.
SAVE
$198K ﹤0.01%
100,000
– –
2022 Q3
1 quarter
SAFE icon
620
PUT
Safehold
SAFE
$848M
$190K ﹤0.01%
2,224
-15,382
-87% -$741K
2021 Q2
6 quarters
SHAK icon
621
PUT
Shake Shack
SHAK
$2.87B
$190K ﹤0.01%
50,000
– –
2022 Q3
1 quarter
CPAAW
622
DELISTED
Conyers Park III Acquisition Corp. Warrants
CPAAW
$178K ﹤0.01%
1,002,144
-10,021
-1% -$1.46K
2021 Q4
4 quarters
RCUS icon
623
PUT
Arcus Biosciences
RCUS
$2.87B
$171K ﹤0.01%
+38,000
New +$1.05M
2022 Q4
0 quarters
AFRM icon
624
PUT
Affirm
AFRM
$26.3B
$165K ﹤0.01%
60,000
– –
2022 Q3
1 quarter
WTI icon
625
PUT
W&T Offshore
WTI
$578M
$165K ﹤0.01%
1,580,400
– –
2021 Q2
6 quarters

Similar funds

UBS O'Connor's Q4 2022 Portfolio in Review

As of Q4 2022, UBS O'Connor held 1,042 positions worth $5.42B, down 38% from $8.8B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

UBS O'Connor withdrew a net $3.75B in Q4 2022, closing 284 positions and reducing 414 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $572M position sold in full.

By sector, the portfolio is most concentrated in Financials at 26% of assets, up from 20% a quarter earlier, followed by Technology and Healthcare.

Against the trend, UBS O'Connor opened a new position in Coupa Software Incorporated worth $128M.

  • UBS O'Connor's largest Q4 2022 buy was Coupa Software Incorporated: 1,619,333 shares worth $128M.
  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022, an estimated $184M increase.
  • UBS O'Connor's biggest Q4 2022 reduction was Rogers Corp, cutting an estimated $219M.
  • UBS O'Connor fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $572M.
  • UBS O'Connor's ten largest holdings make up 41% of its $5.42B portfolio in Q4 2022.
  • UBS O'Connor opened 84 new positions and closed 284 in Q4 2022.
  • UBS O'Connor's portfolio value fell 38% quarter-over-quarter to $5.42B.

Based on UBS O'Connor's 13F filing for Q4 2022, filed 14 Feb 2023.